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This work presents the Australian Clinical Dosimetry Service's (ACDS) ﬁndings of an investigation of
systematic discrepancies between treatment planning system (TPS) calculated and measured audit
doses. Speciﬁcally, a comparison between the Anisotropic Analytic Algorithm (AAA) and other common
dose-calculation algorithms in regions downstream ( 2 cm) from low-density material in anthropo-
morphic and slab phantom geometries is presented. Two measurement setups involving rectilinear slab-
phantoms (ACDS Level II audit) and anthropomorphic geometries (ACDS Level III audit) were used in
conjunction with ion chamber (planar 2D array and Farmer-type) measurements. Measured doses were
compared to calculated doses for a variety of cases, with and without the presence of inhomogeneities
and beam-modiﬁers in 71 audits. Results demonstrate a systematic AAA underdose with an average
discrepancy of 2.9 ± 1.2% when the AAA algorithm is implemented in regions distal from lung-tissue
interfaces, when lateral beams are used with anthropomorphic phantoms. This systemic discrepancy
was found for all Level III audits of facilities using the AAA algorithm. This discrepancy is not seen when
identical measurements are compared for other common dose-calculation algorithms (average
discrepancy 0.4 ± 1.7%), including the Acuros XB algorithm also available with the Eclipse TPS. For slab
phantom geometries (Level II audits), with similar measurement points downstream from in-
homogeneities this discrepancy is also not seen.
Crown Copyright © 2015 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).Introduction
In radiation therapy treatment planning, the dose calculation
algorithm of the treatment planning system (TPS) is relied upon to
accurately calculate the dose and determine the Monitor Units
(MU) to be delivered by the treatment linear accelerator (linac) to
treat a particular tumour. Commercial treatment planning systems
each use a particular ‘brand’ of algorithm [1]. The major (non-full
Monte Carlo) dose calculation algorithms used in TPS are:).
vier Ltd on behalf of Associazione It Superposition [2]
 Collapsed Cone Convolution [3] (CCC)
 Anisotropic Analytical Algorithm [4] (AAA
 Pencil Beam [5,6] (PB)
 Collapsed Cone [7] (CC)
Generally, dose calculation algorithms fall into correction-based
equivalent path-length algorithms and model based algorithms [8]
with electron transport either explicitly accounted for, or neglected.
There is a large body of literature evaluating the performance of
each algorithm both compared to other algorithms/Monte Carlo
[8e12] in clinical scenarios and measurement [13e15]. It is known
that each algorithm has its associated advantages and disadvan-
tages in terms of speed of calculation, accuracy and in dealing withaliana di Fisica Medica. This is an open access article under the CC BY-NC-SA license
Figure 1. A sample CT of the central slice of the Level III phantom including the
measurement points used in the ACDS Level III audit.
L. Dunn et al. / Physica Medica 31 (2015) 435e441436inhomogeneities in both tissue structure and density. Improve-
ments in the accuracy of calculated doses have been shown when
algorithms explicitly consider volume scatter and changes in elec-
tron transport in low/high density regions, such as lung or bone.
In Australia, the Australian Clinical Dosimetry Service (ACDS)
[16] has been performing Level II [17] and Level III audits [18] across
Australian radiotherapy facilities for the past two years. In both
audits, measurements are compared to doses calculated with the
algorithms listed above for both anthropomorphic (Level III) and
slab geometries (Level II). Measurements for both audits are done
onsite by an ACDS audit team using Primary Standards Laboratory
(PSL) calibrated Farmer type ionization chambers and an array of
ionization chambers. To date (2014), 36 Level II and 35 Level III
audits have been performed evaluating various algorithms. Gath-
ering such a large amount of data has allowed the ACDS to begin
identifying systematic, consistent calculation discrepancies be-
tween algorithms for particular phantom measurements. Such a
discrepancy is the topic of this paper.
The AAA dose calculationmodel is a 3D pencil beam convolution
superposition algorithm that has separate modelling for primary
photons, scattered extra-focal photons, and electrons scattered
from the beam limiting devices [19,20]. The AAA algorithm is
convolution based with the dose from each pencil beam, or
beamlet, being calculated through a convolution. Each beamlets’
energy ﬂuence is separated into components for primary and extra-
focal photons and electron contamination. The dose distribution
Db(x,y,z) for beamlet b is calculated using Equation (1) [21,22].
Dbðx; y; zÞ ¼ 4b  Ibðz; rÞ  ∬
b
Kbðx0  x; y0  y; z; rÞ dx0dy0
(1)
Here, the dose is calculated by a convolution of fb, the beamlet's
ﬂuence, Ib, an energy deposition function and a scatter kernel
Kb(x,y,z,r) which deﬁnes the lateral scatter component of the dose.
The scatter kernels are density dependent and calculated in mul-
tiple directions laterally around the beamlet. The total dose calcu-
lated in a patient is a result of a superposition of each beamlet's
contribution.
This paper presents an investigation into systematic discrep-
ancies between TPS calculated and measured audit doses seen
when comparing the AAA algorithm's prediction to other algo-
rithms, in regions adjacent to and downstream from low-density
material in anthropomorphic and slab phantom geometries.Materials and methods
Level III (WAIL) audit
The ACDS Level III Audit [18] determines absorbed dose towater
delivered to selected points in an anthropomorphic phantom (CIRS
IMRT Phantom Model 002LFC (thorax), Computerized Imaging
Reference Systems, Inc., Norfolk, VA, United States). An axial CT slice
of the phantom is shown in Fig. 1. The Level III audit is an “end-to-
end” test of the complete radiotherapy treatment chain. The Level
III audit includes Wedged and Asymmetric ﬁelds with In-
homogeneities in Lung (WAIL). For this audit, ﬁve ACDS prescribed
treatment cases are planned and the dose to selected points, indi-
cated by numbers in Fig. 1, is calculated. Treatment ﬁelds are fully
prescribed by the ACDS using 3D conformal planning for 6 MV
photons only with static gantry and collimation. The details of the
ﬁve cases are shown in Table 1. Cases 2 and 3 are based on cases 2
and 7 from IAEA TECDOC 1583 [23], while the others have been
developed by the ACDS as reference (Case 1) and to further inves-
tigate the impact of the wedge (Cases 4 and 5, added later).Dosimetry measurements are made by an onsite audit team with
PSL calibrated Farmer type ionisation chambers and electrometers.
Measurement locations correspond to the selected calculated
points, which are listed for each case in Table 1 Fig. 1.
To investigate the ﬁndings of this study with the intent of
ﬁnding a practical solution for facilities using the Eclipse AAA dose
calculation algorithm, additional dose calculations were performed
using the Acuros XB algorithm, which is also available with the
Eclipse TPS, (Varian Medical Systems, Palo Alto, CA). Acuros XB is a
modern algorithm which calculates dose to water by directly
solving the Linear Boltzmann Transport Equation (LBTE). The al-
gorithm can also calculate dose-to-medium, however for compar-
ison to the current generation of algorithms evaluated in this study,
only dose towater calculations are presented. Using a CT scan of the
Level III phantom from one facility, absorbed doses per MU were
calculated with AAA and Acuros for all measured points discussed.Level II audit
The ACDS Level II Audit [17] evaluates accuracy of absorbed dose
to water delivered to selected arrays of points at speciﬁc planes
within a “slab” geometry phantom. This is an audit of the beam
model within a treatment planning system, where the simulated
(computer generated) CT of the measurement phantom is supplied
by the ACDS to the Facility for treatment planning. The Level II audit
includes Wedged and Asymmetric ﬁelds with Inhomogeneities for
Lung (WAIL) treatments with sixteen separate single ﬁeld cases
planned. Fields are fully prescribed by the ACDS and underpin the
ACDS Level III (WAIL) Audit. The audit is for 3D planning with 6 MV
photons only with static (zero degree) gantry and collimator angles.
Centres audited planned using their own treatment planning sys-
tems with an ACDS supplied CT to ED (electron density) table.
Dosimetry measurements are made in custom phantoms of CIRS
Solid Water and CIRS Lung materials (Computerized Imaging
Reference Systems, Inc., Norfolk, VA, United States). The detector
used in the Level II audit is a PTW Octavius 729 2D ionisation
chamber array (PTWGmbH, Freiburg Germany). Measurements are
performed at two different depths for each ﬁeld from Case 4e16.
Details of the 16 cases are included in Table 2. Case 1 is not listed in
this table since it is not measured. Case 1 is planned only and
constitutes a 10  10 cm2 ﬁeld with 10 Gy prescribed to the dose
output speciﬁcation point of the facility. This is used to verify that
the treatment planning system calculates 1000 ± 5 MU to be
delivered, as by deﬁnition the dose to the dose output speciﬁcation
point is 1 cGy/MU.
The computer generated CT series (ImSimQA, version 3.0.76a,
Oncology Systems Ltd, Delmar, NY) used in the Level II WAIL Audit
are based on a 30  30  30 cm3 cube of water. Series 1 consists of
Table 1
The measurement cases with the points evaluated in the Level III (WAIL) audit. Additional measurement points (not listed here) are taken for exploratory purposes. Fields are
designated as beam incident from anterior-posterior (AP), left-lateral (LLAT) and right-lateral (RLAT) directions respectively. For the isocentric setups (cases 2e5) the beam
setup point is speciﬁed in parentheses. Further speciﬁc details on beam arrangements can be found in Ref. [18].
Case Field Measurement points Setup Field size Wedge
1 AP 1, 10 SSD ¼ 100 cm 10 cm (SI)  10 cm (LR) None
2 LLAT 1, 4 Isocentric (Point 1) 8 cm (SI)  10 cm (AP) 45 wedge
3 AP 4, 5, 10 Isocentric (Point 3) 10 cm (SI)  12 cm (LR) None
3 LLAT 5 Isocentric (Point 3) 10 cm (SI)  0.6 cm (AP) 30 wedge
3 RLAT 5 Isocentric (Point 3) 10 cm (SI)  0.6 cm (AP) 30 wedge
4 LLAT 2, 3, 4, 5 Isocentric (Point 3) 10 cm (SI)  12 cm (AP) None
5 LLAT 2, 3, 4, 5 Isocentric (Point 3) 10 cm (SI)  12 cm (AP) 60 wedge
Table 2
The cases used in the Level II (WAIL) audit.
CT series Case Measurement depths (cm) SSD (cm) Field size Wedge
1 2 10 90 20 cm (SI)  20 cm (LR) None
1 3 10 90 10 cm (SI)  10 cm (LR) None
1 4 8,15 85 12 cm (SI)  12 cm (LR) None
1 5 8,15 85 12 cm (SI)  12 cm (LR) 30 wedge
1 6 8,15 85 8 cm (SI)  10 cm (LR) None
1 7 8,15 85 8 cm (SI)  10 cm (LR) 30 wedge
1 8 8,15 85 10 cm (SI)  0, 6 cm (LR) None
1 9 8,15 85 10 cm (SI)  0, 6 cm (LR) 60 wedge
1 10 8,15 85 4 cm (SI)  4 cm (LR) None
2 11 8,15 85 12 cm (SI)  12 cm (LR) None
2 12 8,15 85 12 cm (SI)  12 cm (LR) 30 wedge
2 13 8,15 85 8 cm (SI)  10 cm (LR) None
2 14 8,15 85 8 cm (SI)  10 cm (LR) 30 wedge
3 15 8,15 85 10 cm (SI)  0, 6 cm (LR) None
3 16 8,15 85 10 cm (SI)  0, 6 cm (LR) 60 wedge
L. Dunn et al. / Physica Medica 31 (2015) 435e441 437only water. For Series 2 and 3 a 5 cm thick slab of inhale lung is
placedwithin the cube at a depth of 1 cm (to boundary). The central
transverse slices of the three CT series are shown in Fig. 2. Dose
calculations are performed by the facilities on a 1 mm3 dose grid.
Results
Performance of the AAA algorithm in the level III audit
In Fig. 3 the results from the Level III audit are shown for all 12
points downstream from a low density (lung) inhomogeneity;
referring toTable 1 and Fig.1 these points are: Case 2 Points 1 and 4,
Case 3 Point 5 for left and right lateral, Case 4 all points, and Case 5
all points. Each point shows the dose difference/deviation from
ACDS [(planned dose e measured dose)/(measured dose)] relative
to the dose difference of the reference Case 1 Point 1 to eliminate
daily linac output and individual facility dosimetry deviations.
Figure 3 (a) shows the results of audits of facilities using Eclipse
AAA and (b) shows the results of audits using all facilities usingFigure 2. Central transverse slices of (a) CT Series 1, (b) CT Series 2 and (c) CT Series 3. The b
volumes of material equivalent to “inhale” lung tissue.other algorithms. The average difference (±1s) for all the points
calculated with the AAA algorithm is 2.9 ± 1.2% high (Fig. 3a). This
means, following the above given ACDS deﬁnition of difference that
the treatment linacs were underdosing. The average difference and
standard deviation for the points calculated with the other algo-
rithms is 0.4% ± 1.7% (Fig. 3b).
In Fig. 4 the average audit results are shown for individual points
downstream from the lung inhomogeneity. Again, all results have
been normalized to the corresponding reference (Case 1, Point 1) to
eliminate linac output and individual facility dosimetry deviations.
As before, the results are divided into audits with the AAA algo-
rithm and audits with all other algorithms. The 3.0% underdose is
present consistently with all points behind lung when using the
AAA algorithm, regardless of the presence of awedge, depth behind
lung, or distance to ﬁeld edge.
A comparison of calculations with the AAA algorithm to calcu-
lations done with the Acuros algorithm (dose to water) in the same
phantom and planning system are shown in Fig. 5. The diagram
shows differences in dose per MU for the same points in theasic phantom in each series is a 30  30  30 cm3 block of water. Series 2 and 3 include
Figure 3. (a) Level III audit results for points downstream from the lung material for only the points calculated with the AAA algorithm, and (b) Level III audit results for points
calculated with all other algorithms. Differences are deﬁned as (planned dose emeasured dose)/(measured dose) and have each been normalized to the difference of the reference
Case 1 Point 1 to eliminate daily linac output and individual facility dosimetry deviations. Please note that the facility numbers are randomised in each of Figure 3 (a) and (b) and
Facilities 1 e 11 do not correspond to the same facilities for both audits.
L. Dunn et al. / Physica Medica 31 (2015) 435e441438phantom as analysed before. The difference on average was found
to be 2.8% and thereby generally of the same magnitude and in
the opposite direction as the deviation found for the AAA algorithm
calculations in comparison to the measurements across the coun-
try. The exception is Case 2 Point 4, where the difference is smaller
but still in the same direction with 0.85%. These results indicate
that the Acuros XB algorithm largely corrects the erroneous
calculation by the AAA algorithm.
Performance of the AAA algorithm in the level II audit
The Level II results have been analysed and are presented in the
same manner as the Level III results (Figs. 3 and 4). Figure 5 (a)
shows the Level II audit results for all facilities evaluated in the
cases where the measurement point was downstream from the
lung inhomogeneity using the AAA algorithm. Figure 6 (b) shows
the Level II audit results for all facilities excluding those facilitiesFigure 4. Measurement beam speciﬁc average Level III audit result for individual
points downstream from the lung material. The closed circles show the results for only
the AAA algorithm and the open circles shows the results for all other algorithms.
Differences are calculated and normalized as before. Error bars represent the standard
error of the mean.employing the AAA algorithm. Referring to Table 2 and Fig. 2, the
cases that meet these conditions are Cases 11 to 15, points 1 and 3.
The results from Case 16, the asymmetric ﬁeld with 60 wedge are
not included due to the inability of some treatment planning sys-
tem and linac combinations to calculate this ﬁeld accurately [18]. In
Fig. 7, each point shows the average dose discrepancy between
measured and planned doses, relative to the dose difference of the
reference Case 2 Point 1 to eliminate daily linac output and indi-
vidual facility dosimetry. The distinct 3.0% offset present in the
Level III audit results (Figs. 3 and 4) is not seen for the Level II audit,
with the average discrepancy for AAA and other algorithms with
themean and standard deviation of the average differences for AAA
and all other algorithms found to be 0.2 ± 0.7% and 0.7 ± 0.9%
respectively.
Discussion
The data presented in this manuscript demonstrates a pecu-
liarity of the AAA algorithm, as implemented in the Varian Eclipse
TPS. For curved, ‘patient realistic’ inhomogeneities such as thoseFigure 5. Difference in dose per MU for the points of level III audits when calculated
using the Acuros (dose to water) vs the AAA algorithm.
Figure 6. Level II audit results for (a) AAA algorithm and (b), audits excluding those facilities implementing the AAA algorithm. Measurement cases and points downstream from
the lung interface are shown. All individual dose differences have been normalized to the dose difference of the reference Case 2 Point 1 to eliminate daily linac output and in-
dividual facility dosimetry deviations. The mean and standard deviation of the average differences for AAA and all other algorithms is 0.2 ± 0.7% and 0.7 ± 0.9% respectively.
L. Dunn et al. / Physica Medica 31 (2015) 435e441 439present in the CIRS thorax phantom, the AAA algorithm consis-
tently calculates a higher dose than is measured. On average, this
difference amounts to approximately 3.0% when the measure-
ment point is downstream from the lung inhomogeneity in tissue
equivalent material. Other algorithms, tested in the same manner
do not show this behaviour. The systematic discrepancy of the
AAA algorithm was not found when the phantom and the in-
homogeneity were of a rectilinear slab geometry. Here, on
average, the AAA algorithm calculated the dose actually more
accurately, though not signiﬁcantly higher than the average of the
other algorithms (0.2 ± 0.7% and 0.7 ± 0.9% mean ± SD,
respectively).Figure 7. The average Level II audit results (Figure 5) for the centre of ﬁeld points for
individual cases behind lung. The closed circles show the results for only the AAA
algorithm and the open circles shows the results for all other algorithms. All individual
dose differences have been normalized to the dose difference of the reference Case 2
Point 1 to eliminate daily linac output and individual facility dosimetry deviations.
Error bars represent the standard error of the mean.This could potentially be a problem if commissioning mea-
surements for a Varian Eclipse TPS are done with rectilinear
phantoms. In end-to-end tests, which are generally also performed
as part of the commissioning, any algorithm rooted deviations
might be diminished by other small deviations or might be within
the larger allowed tolerances for such tests [24].
There are a number of experimental studies for which the AAA
algorithm has been shown to be accurate in both homogeneous and
heterogeneous geometries [21,25e27]. Ronde et al. [28] investi-
gated two-dimensional dose distributions for a variety of different
ﬁeld conﬁgurations in solid water with a 2D array of ion chambers,
as well as patient speciﬁc treatment plans in a thorax lung phantom
with Gafchromic ﬁlms. Their study found that the AAA algorithm
was superior to the PBC algorithm in heterogeneous media, espe-
cially for 15 MV. Furthermore, when measuring in a thorax phan-
tom, the deviations between planned and measured doses in lung
and mediastinum regions was found to be less than their speciﬁed
criteria of 3% in dose and 3 mm in distance-to-agreement (DTA)
respectively.
Van Esch et al. [4] tested the accuracy of AAA for different ﬁeld
sizes (symmetric and asymmetric) for open ﬁelds, wedged ﬁelds,
and static and dynamicmulti-leaf collimation ﬁelds. Measurements
were performed on homogeneous (water equivalent), phantoms
containing cork inhomogeneities, and on the thorax of an anthro-
pomorphic phantom. Their measurements demonstrated that at
the interface between solid water and cork, dose proﬁles showed a
better agreement with AAA compared to Pencil Beam. Depth dose
curves in the cork were also improved substantially with AAAwhen
compared to Pencil Beam models. For the thorax phantom dose
measurements, the agreement between planned and measured
doses was found to be mostly within 5%. This result is not in
disagreement with the results presented in Fig. 3, though the sys-
tematic offset of 3% was not reported, possibly due to the assess-
ment criteria of 5%.
Bragg et al. [29] compared predicted and measured dose
distributions with ion chamber and ﬁlm measurements in ho-
mogeneous and inhomogeneous phantoms, with simple and
complex ﬁelds. The effect of inhomogeneities was investigated
using a range of phantoms constructed of water, bone and lung
substitute materials. Simulated treatment plans were also
L. Dunn et al. / Physica Medica 31 (2015) 435e441440delivered to an anthropomorphic phantom and the delivered
doses compared to the doses predicted by the Anisotropic
Analytical Algorithm. For homogeneous phantoms, Bragg et al.
found that the agreement was within 2% and 2 mm DTA in most
instances. When heterogeneities were present, discrepancies
between measured and planned doses were generally found to
be within 2.5% for slab and anthropomorphic phantoms
respectively.
In contrast to the above studies, Robinson [30] evaluated the
ability of the AAA algorithm to accurately account for the presence
of inhomogeneities in simple geometries by comparing calculated
and measured doses. The study used a planar geometry phantom
consisting of upper and lower layers of Solid Water separated by a
heterogeneity region of variable thickness modelled in Eclipse. The
goal of 2% accuracy in correcting for heterogeneities, as set out by
the American Association of Physicists in Medicine Task Group 65
[31] was used as the criteria for evaluation. In general, over all non-
unit density materials examined, the AAA was found to over-
predict (number of MUs for actual treatment delivery would
result in a dose deﬁciency) dose beyond low-density regions and in
many cases, the deviation between the AAA and experimental re-
sults exceeds the Task Group 65 target of 2%. The source of these
deviations was speculated to arise from an inability of the AAA
algorithm to correctly account for altered attenuation along pri-
mary ray paths.
National/international audit programs to combine multi-centre
data and can thus leverage a statistical power to identify corre-
lations which are invisible within, or to, a single facility. The
dosimetric discrepancy identiﬁed and quantiﬁed by the ACDS
while mentioned in the published literature, has gone unnoticed
or underestimated by individual facilities. These results reinforce
the case that independent external dosimetric auditing is an
invaluable tool for improving, and validating, the accuracy of ra-
diation therapy. Kry et al. [32] and the Imaging and Radiation
Oncology Core (IROC e Houston) group, further demonstrate the
utility and value of such multi-centre auditing. Their study
compared institution patient-speciﬁc IMRT QA plans to the results
of their independent credentialing using a head phantom. The
study found that in-house IMRT QA failed to detect unacceptable
plan delivery as measured independently in an IROC head and
neck phantom and concluded that IMRT QA was not a reasonable
replacement for a credentialing (audit) phantom irradiation. In a
similar study to the work presented here, Kry et al. [24] used a
thorax phantom for a large (n ¼ 221 different institutions, 304
irradiations) credentialing study that looked at the impact of dose
calculation algorithm and their accuracy when accounting for
heterogeneities. Measured doses were compared to calculated
doses for a lung target and analysed as a function of calculation
algorithm. Their results showed that the AAA algorithm as well as
convolution-superposition algorithms overestimated the dose that
was delivered to the target by 3.7% on average. Though direct
comparisons cannot be made between the results presented here
owing to the nature of the audits performed (in lesion surrounded
by lung, versus in tissue downstream from lung), it is probable
that such a systematic discrepancy may not have been uncovered
were it not for the multi-centre audit.
A large European study by Gershkevitsh et al. [33] conducted
TPS audits in 60 radiotherapy centres using the TECDOC 1583
methodology also employed in the Level III audit presented here.
In total, 190 data sets (combination of algorithm and beam
quality) were collected and analysed. Their study found that
dosimetry problems requiring interventions were discovered in
about 10% of datasets and deﬁcient beam modelling in TPSs was
discovered in a number of cases. Like the RPC and ACDS audit
programs, the IAEA European audit contributed to achieving abetter understanding of the performance of TPSs and helped to
resolve issues related to imaging, dosimetry and treatment
planning. Furthermore, their study also found similar discrep-
ancies for the Varian AAA algorithm however the results were
attributed to input beam data and beam modelling. Similar Eu-
ropean and South American audits have also been reported and
shown to be effective [34,35].
The results in this work have not been reported by previous
studies, employing similar anthropomorphic phantoms. The
possible reasons for this are the use of wider overall dose delivery
tolerances of 5% [36], resulting in measurements with 3% discrep-
ancy still passing the acceptance criteria. The Level III audits in this
work are conducted on onsite audits using directly PSL calibrated
Farmer type ionization chambers and electrometers resulting in
low measurement uncertainties and allowing for tight action-level
tolerances. The contribution of other factors, such as incorrect
beam modelling and input data as reported in Gershkevitsh et al.
[33] may also have contributed to the oversight of the systematic
nature of the discrepancy.
Conclusion
This work has demonstrated a systematic underdosing that
occurs when the AAA algorithm is compared to measurements in
the mediastinum region of an anthropomorphic thorax phantom,
with lateral beams passing through lung. This systematic offset,
which was absent for identical comparisons with other algo-
rithms, results in an average discrepancy of 3% between planned
and measured doses. This result, common amongst separate in-
stitutions using the same dose calculation algorithm and param-
eters, may have otherwise been overlooked by individual
facilities, and was underestimated by others. An independent
external auditing process was required to identify the dosimetric
issue.
The ACDS Level III audit (as well as the Level II) has an out-of-
tolerance level of 5% and discrepancies between measured and
planned doses of 3% did not necessarily result in out-of-tolerance
audit outcomes. However, the systematic discrepancy due to the
AAA algorithm, when compounded with other errors in the treat-
ment planning and delivery chain more often resulted in discrep-
ancies outside the optimal level (3.3% difference between
measured and planned dose) in comparison to other algorithms for
the same measurements.
The potential implication of this ﬁnding in clinical scenarios is
lower tumour control probability for lesions downstream from
lung, for example, lung and mediastinal tumours when the AAA
algorithm is used. Additionally, other sources of uncertainty in the
radiotherapy treatment chain and dosimetry may compound
together to result in a clinically relevant dose discrepancy between
what was planned and actually delivered to the patient. Conversely,
other sources may compensate for the calculation discrepancy,
hiding the issue. We speculate that the reason for the results pre-
sented in this work is that AAA uses Gaussian functions to describe
the mean heterogeneous effect in just four lateral directions,
instead of over 4p as implemented in the Acuros XB algorithm.
Therefore, a solution for facilities with the Eclipse TPS is to consider
the use of the Acuros XB dose calculation algorithm, which appears
to generally handle most of the situations investigated with the
ACDS Level III audits more accurately.
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